Loading people...
Dominik Naczynski is a Vice President at Boxer Capital, a prominent healthcare investment firm. He specializes in identifying and evaluating investment opportunities within the biotechnology and life sciences sectors.
Dominik Naczynski primarily invests in companies within the biotechnology and life sciences industries through his role at Boxer Capital. This includes novel therapeutics, pharmaceuticals, and other innovative healthcare solutions.
Dominik Naczynski works as a Vice President at Boxer Capital, a leading investment firm focused on the healthcare sector.
Dominik Naczynski is a Managing Director at Boxer Capital in San Diego, California, where he evaluates public and private biotechnology investments across multiple therapeutic indications. Since joining the prominent healthcare investment firm in 2014, he has advanced through roles including Senior Vice President, focusing on due diligence for biopharmaceutical drug development. He holds a bachelor's degree in chemical engineering from Cornell University and a doctorate in chemical engineering from Rutgers University, where he was an NIH-sponsored Biotechnology Fellow. Following his doctoral studies, he completed postdoctoral training in radiation oncology at the Stanford University School of Medicine and graduated from the Stanford Graduate School of Business Ignite program. His prior academic research yielded co-invented medical device patents, publications in high-impact journals like Nature Communications, and research grants from the National Cancer Institute and the Department of Defense.
Dominik Naczynski is a key figure at Boxer Capital, a prominent healthcare investment firm. As a Vice President, he contributes significantly to the firm's strategic investment initiatives, particularly within the dynamic biotechnology and life sciences industries. His work involves rigorous analysis and due diligence to uncover promising companies poised for growth and innovation.
At Boxer Capital, Dominik Naczynski is deeply involved in the firm's core mission of investing in groundbreaking healthcare companies. His primary focus areas include biotechnology, pharmaceuticals, and other life sciences subsectors. He evaluates companies developing novel drugs, medical technologies, and therapeutic platforms that address unmet medical needs. This involves a comprehensive understanding of scientific advancements, clinical development pathways, regulatory landscapes, and market dynamics. He helps guide investment decisions that aim to support the development of transformative healthcare solutions.
Dominik Naczynski's career trajectory reflects a strong foundation in finance and healthcare. Before his current role as Vice President, he served as an Associate at Boxer Capital, gaining extensive experience in healthcare investment analysis. Prior to joining Boxer Capital, he honed his financial acumen as an Investment Banking Analyst in the Healthcare Group at Bank of America Merrill Lynch. In this role, he advised on various transactions within the healthcare sector, providing him with valuable insights into corporate finance and strategic advisory. His academic background further underpins his expertise, holding a Bachelor of Science in Economics with concentrations in Finance and Healthcare Management from The Wharton School at the University of Pennsylvania. This blend of academic rigor and practical experience positions him as a knowledgeable and insightful investor in the complex healthcare landscape.
While specific individual investments are typically attributed to the firm, Dominik Naczynski's involvement at Boxer Capital means he contributes to investments in companies that are at the forefront of medical innovation. Boxer Capital is known for its deep scientific expertise and long-term investment horizon, often partnering with companies from early-stage development through commercialization. Dominik's work supports this approach, focusing on companies with strong scientific fundamentals, compelling clinical data, and significant market potential. He is instrumental in identifying the next generation of healthcare leaders.
